-
2024-518909-18-00
5
2021-03-23
HIV-1 infected individuals currently taking an INSTI-based three-drug
-
2022-502606-33-00
5
2021-02-26
Patients with histologically or cytologically documented non-squamous
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2024-512232-30-00
10
2021-01-18
Primary Biliary Cholangitis
-
2023-506911-16-00
5
2020-12-04
ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
-
2023-506576-27-00
5
2020-09-30
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
-
2022-502887-19-00
5
2020-08-18
Diffuse Large B-Cell Lymphoma
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2024-516532-97-00
9
2020-03-26
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
-
2024-510887-22-00
5
2019-09-30
Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
-
2024-511641-18-00
4
2019-08-01
Diffuse Large B-cell Lymphoma ABC
-
2023-505223-31-00
4
2019-06-14
Localized ER+ breast cancer
-
2023-509834-20-00
4
2019-03-13
untreated FLT3-mutated Acute Myeloid Leukemia
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2024-511204-16-00
5
2019-01-23
Metastatic breast cancer
-
2023-510009-16-00
9
2018-12-04
Acute Myeloid Leukemia
-
2023-508463-71-00
5
2018-11-30
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
-
2024-512049-17-00
6
2018-09-05
Newly diagnosed MM patients >= 65 years old or ineligible for autologo
-
2023-508018-41-00
4
2018-07-27
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2023-504820-24-00
5
2018-03-21
Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-507500-31-00
10
2017-08-22
Advanced or metastatic Non-small cell lung cancer (NSCLC)